Mice Missing a Newly Mapped Kidney Protein Die Sooner From Calcified Arteries, Putting Phosphate on the Longevity Map for the 37 Million Americans With Kidney Disease

Most longevity headlines chase glamorous targets: senescent cells, reprogramming, GLP-1 drugs. A study highlighted this week by the University of Colorado Anschutz points somewhere far less fashionable, at a mineral that sits on almost every nutrition label. Researchers there have shown that mice lacking a kidney protein called TMEM174 cannot keep phosphate in check, develop stiff, calcified blood vessels and live significantly shorter lives, and that a lower-phosphate diet blunts much of the damage.

The work, led by research professor Makoto Miyazaki with Jose G. Miranda and Judith Blaine and published in Scientific Reports, adds a concrete molecular lever to an old observation: the more phosphate circulating in the blood, the shorter an animal tends to live. “Phosphate is really underestimated in terms of longevity in all mammals,” Miyazaki said in the university’s release, carried by Medical Xpress on November 17.

What the researchers found

The kidneys constantly filter phosphate out of the blood. A transporter protein called NPT2A then pulls roughly three-quarters of it back into circulation so the body does not lose too much, according to the university’s summary. TMEM174 acts as a brake on that recycling: it binds to NPT2A and, as the paper describes, helps pull the transporter off the cell surface so it can be degraded.

When that brake is missing, phosphate builds up. The paper’s key findings include:

  • TMEM174 knockout mice in two genetic backgrounds (C57BL6/J and DBA/2J) had significantly shorter lifespans than normal controls.
  • Feeding the mice a high-phosphate diet (1.2% versus 0.6%) worsened vascular calcification, vessel stiffness and mortality, while a low-phosphate diet rescued those effects.
  • In cell experiments, the C-terminal tail of TMEM174 proved essential: versions missing that region could not bind or degrade NPT2A, which the authors flag as a potential therapeutic target.

The mechanism behind the damage is well understood. Chronically high phosphate pushes smooth muscle cells in artery walls to behave like bone-forming cells and lay down calcium phosphate crystals, turning flexible vessels rigid. Stiff arteries raise the risk of cardiovascular disease and early death, which is why vascular calcification is often described as a form of premature vascular aging.

The finding builds on the same group’s earlier 2022 Scientific Reports paper identifying Tmem174 as a regulator of the phosphate transporter that prevents hyperphosphatemia. “Scientists have been studying phosphate homeostasis for over 100 years, so to still find a new protein that regulates phosphate is kind of unique,” Miyazaki said.

Why kidney patients are the first audience

Elevated blood phosphate is uncommon in the general population but widespread in chronic kidney disease, because failing kidneys lose their ability to clear it. The numbers are large. The CDC, in national estimates updated in March 2026, says more than 1 in 10 U.S. adults, about 37 million people, are estimated to have CKD. Prevalence reaches 34% among people 65 and older, and about 87% of adults with CKD do not know they have it.

The Colorado team notes that TMEM174 deficiency appears to be driven mainly by genetics rather than by kidney disease itself. But patients who have CKD and also carry low TMEM174 activity could face compounding risks, and a drug that mimics the protein’s braking action could in principle help any patient struggling to control phosphate.

The business angle: food, pharma and payers

For business readers, the study matters less as a cure and more as a signal about where healthy-aging value may be created over the next decade.

Drug developers. Today, managing phosphate in kidney patients leans heavily on diet restrictions and binder pills taken with meals. A target that acts upstream, on how much phosphate the kidney reabsorbs in the first place, is a different approach. The paper’s identification of a specific protein region required for the effect gives medicinal chemists something concrete to aim at, although any therapy is still years away and would need to clear human trials.

Food and beverage companies. The university’s release points out that phosphate additives used in processed foods, deli meats and sodas are absorbed faster and more completely than the phosphate found naturally in whole foods. As consumers and regulators pay more attention to ultra-processed food, research that links phosphate load to vascular aging adds another reason for brands to rethink additive-heavy formulations, and gives “better-for-you” product lines a science-backed talking point.

Insurers and employers. Kidney disease and cardiovascular disease are costly, long-running conditions to manage, and the CDC’s finding that most people with CKD are undiagnosed means many workers are carrying risk nobody is tracking. Cheap blood tests for kidney function and phosphate, paired with dietary coaching, are the kind of low-cost prevention that wellness programs can fund now, without waiting for a new drug.

Longevity investors. The field has poured money into cellular rejuvenation platforms. This study is a reminder that mineral metabolism, a quieter corner of physiology, also shapes how fast the body ages. Mapping the regulators of everyday nutrients may yield targets that are easier to measure and validate in people than many headline aging mechanisms.

The caveats

This is mouse and cell work. A knockout mouse that lacks a protein entirely is an extreme model, and the high-phosphate diet used here is designed to stress the system. The researchers say they still do not fully understand how TMEM174 destabilizes NPT2A, and Miyazaki acknowledged that diet alone may be hard to rely on, because phosphate is present in so many foods. Nothing in the study shows that lowering phosphate extends lifespan in healthy people.

The bottom line

TMEM174 will not become a household name soon, but the study sharpens a practical message: phosphate balance looks like a real, modifiable lever on vascular aging, especially for the tens of millions of Americans with kidney disease. For drugmakers it is a new target, for food companies a formulation question, and for employers and insurers a prompt to screen earlier and cheaper.

Never miss a patient call. Clinics, labs and wellness practices fielding questions about kidney health and healthy aging can let MAJ.COM Voice AI answer every inbound call 24/7, book appointments and follow up on outbound outreach, so no lead or patient slips through. Discover MAJ.COM Voice AI

Edited by Coron @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous


Discover more from QUE.com

Subscribe to get the latest posts sent to your email.

Coron @QUE.COM

Editor at QUE.com Intelligence.

coronquecom has 171 posts and counting.See all posts by coronquecom

Leave a Reply

Connect with

Discover more from QUE.com

Subscribe now to keep reading and get access to the full archive.

Continue reading